AGYS lifts its FY27 outlook as subscription sales, backlog deployment and PMS adoption strengthen Q1 results.
Agilysys, Inc. (AGYS) Q1 2027 Earnings Call Transcript
Agilysys (AGYS) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.33 per share a year ago.
Although the revenue and EPS for Agilysys (AGYS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Agilysys NASDAQ: AGYS reported record fiscal 2027 first-quarter revenue, subscription revenue and profitability, prompting the hospitality software provider to raise its full-year revenue outlook.
AGYS' Q1 hinges on subscription growth, Marriott deployment progress and early updates on its new AI-driven modules.
Amid supply-chain woes, Computer - Integrated Systems players like MU, STX, HPE and AGYS benefit from the demand for integrated solutions and multi-cloud model adoption.
Investors need to pay close attention to AGYS stock based on the movements in the options market lately.
Agilysys (AGYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Agilysys (AGYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The consensus price target hints at a 45.5% upside potential for Agilysys (AGYS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
During the first quarter of 2026, the largest portfolio sector weightings were Health Care and Industrials. RBC Bearings Incorporated, Cognex Corporation and Nebius Group were among the top contributors to performance. Repligen Corporation, Agilysys, Inc., and GeneDx Holdings Corp. were among the top detractors from performance.